Ikarian Capital’s Solid Biosciences SLDB Stock Holding History

Ikarian Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-424,000	Closed	-$2.39M	–	206
2025 Q4	$2.39M	Sell	424,000 -44,000	-9%	-$238K	0.19%	95
2025 Q3	$2.89M	Buy	+468,000	New	+$2.74M	0.29%	83
2025 Q1	–	Sell	-300,000	Closed	-$1.2M	–	211
2024 Q4	$1.2M	Hold	300,000	–	–	0.16%	99
2024 Q3	$2.09M	Buy	+300,000	New	+$2.43M	0.29%	73
2020 Q2	–	Sell	-29,987	Closed	-$1.07M	–	207
2020 Q1	$1.07M	Buy	29,987 +9,614	+47%	+$476K	0.08%	120
2019 Q4	$1.36M	Buy	+20,373	New	+$2.25M	0.22%	72

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital's SLDB Position: Q2 2026 in Review

Ikarian Capital reduced its Solid Biosciences (SLDB) stake by 84% in Q2 2026, selling an estimated $1.68M and leaving 42,956 shares worth $429K. The position accounts for 0.05% of the portfolio, ranked #124.

Ikarian Capital first reported a position in SLDB in Q1 2020 and has held it in 14 quarters since. The position peaked at $5.97M in Q4 2020. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Ikarian Capital held 42,956 shares of Solid Biosciences worth $429K as of Q2 2026.
Ikarian Capital sold 221,453 Solid Biosciences shares in Q2 2026, an estimated $1.68M.
Solid Biosciences made up 0.05% of Ikarian Capital's portfolio in Q2 2026, its #124 holding.
Ikarian Capital first reported a position in Solid Biosciences in Q1 2020 and has held it in 14 quarters since.
Ikarian Capital's Solid Biosciences position peaked at $5.97M in Q4 2020.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.